

Kindly add the following new claims 17 and 18.

17. A composition comprising:

(a) Chlamydia infection inhibiting amount of a molecule that interacts with insulin-like growth factor; and
(b) a pharmaceutically acceptable carrier, diluent or excipient.

18. The composition of claim 17, wherein said molecule is an antibody.

REMARKS

I. On page 3 of the Office Action, claims 1-4, 6 and 8 were rejected under 35 USC § 102(b) over van Ooij et al.

According to the Examiner, the reference discloses a monoclonal antibody to mannose-6-phosphate receptor.

The rejection is traversed for the following reasons.

The instantly claimed invention relates to a Chlamydia infection inhibiting amount of a molecule along with a pharmaceutically acceptable carrier.

Van Ooij et al. used antibodies in vitro as markers of endosomes and thus those antibodies are not specific for Chlamydia-infected cells. Van Ooij et al. do not teach either of those elements noted above as to the claimed invention and thus anticipation does not exist. Accordingly, the rejection must be removed.

II. At the bottom of page 3 of the Office Action, claims 1 and 8 were rejected under 35 USC § 102(b) over the 1996 Journal of Clinical Investigation paper where the Examiner alleged that the composition taught therein, comprising a molecule containing mannose-6-phosphate, inhibits AAV infection.

The rejection is traversed for the following reasons.

Kuo et al. teach high-mannose type-oligosaccharides expressed at the MOMP of the organism. Kuo et al. do not teach mannose-6-phosphate. At best, Kuo et al. teach molecules with multiple mannose residues. Please note in Tables 1 and 2 that the designations of 6, 7, 8 or 9 refer to the number of mannose residues in a structure.

Thus Kuo et al. do not teach the claimed invention and the rejection must be removed.

III. On page 4 of the Office Action, claims 1-8 were rejected under 35 USC § 102(a) over Lin et al.

The rejection is traversed for the following reasons.

Lin et al. do not teach the claimed invention. The rejection is improper and must be removed.

CONCLUSION

Applicants have taken steps to bring the application in condition for allowance. Reexamination, reconsideration, withdrawal of the rejections and early indication of allowance

Amendment
KUO et al.
U.S. Ser. No. 09/910,920

are solicited earnestly. If any issues remain unresolved, the Examiner is urged to contact the undersigned at the local exchange noted hereinbelow.

Respectfully submitted,



Dean H. Nakamura
Attorney for Applicants
Reg. No. 33,981

Roylance, Abrams, Berdo
& Goodman L.L.P.
1300 19th Street, N.W., Suite 600
Washington, D.C. 20036-2680
(202) 659-9076
Dated: 10 December 2002

MARKED UP CLAIM

1. **(Amended)** A composition comprising:
 - (a) a Chlamydia infection inhibiting amount of a molecule that interacts with mannose-6-phosphate[,] or mannose-6-phosphate receptor [or insulin-like growth factor-2]; and
 - (b) a pharmaceutically acceptable carrier, diluent or excipient.